Abstracts tagged "Psoriatic arthritis"

Abstract Number: 667 • 2015 ACR/ARHP Annual Meeting
Comparison of Patient and Provider Assessments of Response to Therapy for Psoriatic Arthritis
Tobee Gunter¹ and Jessica Walsh², ¹Rheumatology, School of Medicine, University of Utah Internal Medicine, Salt Lake City, UT, ²Division of Rheumatology, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT
Background/Purpose: Little is known about how psoriatic arthritis patients and their providers perceive response to therapy. Discrepancies in perceptions of therapy response may indicate that…
Abstract Number: 2873 • 2015 ACR/ARHP Annual Meeting
Pharmacological Treatment of Psoriatic Arthritis (PSA): Systematic Literature Review for the Update of the EULAR Recommendations for the Management of PSA
Sofia Ramiro¹, Josef S. Smolen², Robert B.M. Landewé³, Désirée van der Heijde¹, Maxime Dougados⁴, Paul Emery⁵, Maarten de Wit⁶, Maurizio Cutolo⁷, Susan Oliver⁸ and Laure Gossec⁹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Rheumatology Department, Cochin hospital, Paris-Descartes University, Paris, France, ⁵Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, ⁶EULAR Social Leagues, Zurich, Switzerland, ⁷Division of Clinical Immunology, Dept Internal Medicine, University of Genova, Genova, Italy, ⁸Independent Nurse Consultant, North Devon, United Kingdom, ⁹Rheumatology, Pitié Salpetriere Hospital, Paris, France
Background/Purpose: As part of the update of the EULAR recommendations for the management of PsA, we performed a systematic literature review to assess the efficacy…
Abstract Number: 670 • 2015 ACR/ARHP Annual Meeting
Evaluation of the Predictive Value of Non-Specific Musculoskeletal Symptoms in Preclinical Phases of Psoriatic Arthritis
Lihi Eder¹, Ari Polachek¹, Cheryl Rosen², Vinod Chandran¹, Richard J. Cook³ and Dafna D. Gladman¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: Limited information exists about the characteristics of pre-clinical phases of psoriatic arthritis (PsA). We aimed to assess whether the presence and trends in non-specific…
Abstract Number: 2874 • 2015 ACR/ARHP Annual Meeting
Two-Years Survival of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis and Predictors Thereof in Real-Life Settings
Leonardo Santo¹, Angelo Semeraro², Carmelo Zuccaro³, Maria Grazia Anelli⁴, Romano Bucci⁵, Antonio Marsico⁶, Laura Quarta⁷, Giorgio Carlino⁸, Francesco Paolo Cantatore⁹, Annamaria Gaudio¹⁰, Fabio Cacciapaglia¹¹, Oriana Casilli¹², Paola Chiara Francesca Falappone¹³ and Florenzo Iannone¹⁴, ¹DSS4 Barletta, ASL BT Andria - Rheumatology Service, Barletta, Italy, ²Unità Operativa di Reumatologia ASL Taranto, Taranto, Italy, ³U.O.of Geriatrics, Outpatient clinic of Rheumatology, Brindisi, Italy, ⁴DIM, Rheumatology Unit, Bari, Italy, ⁵A.O.U., Rheumatology Hospital Unit, Foggia, Italy, ⁶Outpatient clinic of Rheumatology, Taranto,, Italy, ⁷Department of Rheumatology, "V.Fazzi" Hospital, San Cesario di Lecce, Italy, ⁸ASL LE - DSS Casarano and Gallipoli, Rheumatology Service, Gallipoli, Italy, ⁹Department of Rheumatology, University of Foggia,, Foggia, Italy, ¹⁰Department of Rheumatology, University of Foggia, Foggia, Italy, ¹¹Internal Medicine Unit and Outpatient clinic of Rheumatology, “N. Melli” Hospital, San Pietro Vernotico (BR), Italy, ¹²Department of Rheumatology, "Vito Fazzi" Hospital, San Cesario di Lecce, Italy, ¹³Internal Medicine Unit - Outpatient clinic of Rheumatology,, "S. Camillo de' Lellis" Hospital, Mesagne (BR), Italy, ¹⁴Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy
Background/Purpose: It has previously been shown that the survival of anti-TNF drugs was lower in Rheumatoid arthritis (RA) than in other chronic arthritis1. The objective…
Abstract Number: 675 • 2015 ACR/ARHP Annual Meeting
Vitamin D Deficiency in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis. Results of the CARMA Study
Ana Urruticoechea¹, Maria Auxiliadora Martin², Santos Castañeda³, Carlos Alberto Sánchez-Piedra², Carlos González-Juanatey⁴, Javier Llorca⁵, Federico Díaz-González⁶ and Miguel Angel Gonzalez-Gay⁷, ¹Hospital Can Misses, Ibiza, Spain, ²Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ³Rheumatology, H.U. La Princesa, Madrid, Spain, ⁴Division or Cardiology, Hospital Lusus Augusti, Lugo, Spain, ⁵Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁶Investigation Unit, Sociedad Española de Reumatológía, Madrid, Spain, ⁷Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: To study the association between 25-hydroxyvitamin D (25(OH)D) levels and the clinical characteristics of patients with chronic inflammatory rheumatic diseases (CIRD). Methods: Cross section…
Abstract Number: 2888 • 2015 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III, Randomized, Controlled Trials
Dafna D. Gladman¹, Arthur Kavanaugh², Adewale O. Adebajo³, Juan J. Gomez-Reino⁴, Jürgen Wollenhaupt⁵, Maurizio Cutolo⁶, Georg A. Schett⁷, Eric Lespessailles⁸, Melissa McIlraith⁹, ChiaChi Hu⁹, Christopher J. Edwards¹⁰, Charles A. Birbara¹¹ and Philip J. Mease¹², ¹Toronto Western Hospital, Toronto, ON, Canada, ²University of California, San Diego School of Medicine, LaJolla, CA, ³University of Sheffield, Sheffield, United Kingdom, ⁴Hospital Clinico Universitario, Santiago, Spain, ⁵Schön Klinik Hamburg Eilbek, Hamburg, Germany, ⁶University of Genova, Genova, Italy, ⁷University of Erlangen-Nuremberg, Erlangen, Germany, ⁸University of Orléans, Orléans, France, ⁹Celgene Corporation, Warren, NJ, ¹⁰University Hospital Southampton, Southampton, United Kingdom, ¹¹University of Massachusetts Medical School, Worcester, MA, ¹²Rheumatology Research, Swedish Medical Center, Seattle, WA
Background/Purpose: Apremilast (APR), a PDE4 inhibitor, helps regulate immune responses in psoriatic arthritis (PsA). PALACE 1, 2, and 3 compared apremilast (APR) efficacy/safety with placebo…
Abstract Number: 677 • 2015 ACR/ARHP Annual Meeting
Satisfaction in Psoriatic Arthritis Patients Despite Active Joint Disease
Daniel E. Furst¹, Emma Sullivan², James Pike³, James Piercy⁴, Jacqueline Palmer⁵ and Vivian Herrera⁵, ¹Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Adelphi Real World, Manchester, United Kingdom, ³Statistics, Adelphi Real World, Macclesfield, United Kingdom, ⁴Adelphi Real World, Macclesfield, United Kingdom, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Psoriatic Arthritis (PsA) is a chronic immune-mediated condition with multiple manifestations; joint inflammation with subsequent joint damage is a key component. Across a number…
Abstract Number: 2889 • 2015 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor: Improvements in Nail and Scalp Psoriasis and Psoriasis Area and Severity Index in Patients with Moderate to Severe Plaque Psoriasis
Kim Papp¹, Jeffrey Crowley², Carle Paul³, Melinda Gooderham⁴, Kristian Reich⁵, ChiaChi Hu⁶, Robert M. Day⁶ and Christopher E.M Griffiths⁷, ¹Probity Medical Research, Waterloo, ON, Canada, ²Bakersfield Dermatology, Bakersfield, CA, ³Toulouse University, Hôpital Larrey, Toulouse, France, ⁴SKiN Centre for Dermatology and Probity Medical Research, Peterborough, ON, Canada, ⁵SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany, ⁶Celgene Corporation, Warren, NJ, ⁷Dermatology Centre, University of Manchester, Manchester, United Kingdom
Background/Purpose: Scalp and nail psoriasis are difficult-to-manage manifestations of psoriasis and psoriatic arthritis (PsA). Nail involvement occurs in ~80% of pts with PsA and can…
Abstract Number: 682 • 2015 ACR/ARHP Annual Meeting
Misalignment Between Physician and Patient Satisfaction with Current Psoriatic Arthritis Treatment
Daniel E. Furst¹, Emma Sullivan², James Pike³, James Piercy⁴, Jacqueline Palmer⁵ and Vivian Herrera⁵, ¹Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Adelphi Real World, Manchester, United Kingdom, ³Statistics, Adelphi Real World, Macclesfield, United Kingdom, ⁴Adelphi Real World, Macclesfield, United Kingdom, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Psoriatic Arthritis (PsA) is a chronic immune related condition affecting the joints and commonly occurs alongside psoriasis. Well-established physician patient relationships are instrumental to…
Abstract Number: 2891 • 2015 ACR/ARHP Annual Meeting
Assessment of Disability Levels in a Cohort of 1,489 Patients with Active Psoriatic Arthritis, and the Effect of Apremilast Treatment: Pooled Data from Three Phase III, Randomized, Controlled Trials
Philip J. Mease¹, Jürgen Wollenhaupt², Stephen Hall³, Filip van Den Bosch⁴, Eric Lespessailles⁵, Melissa McIlraith⁶, Lichen Teng⁶ and Christopher J. Edwards⁷, ¹Rheumatology Research, Swedish Medical Center, Seattle, WA, ²Schön Klinik Hamburg Eilbek, Hamburg, Germany, ³Monash University, CabriniHealth, Melbourne, Australia, ⁴Rheumatology, Ghent University Hospital, VIB, Ghent, Belgium, ⁵University of Orléans, Orléans, France, ⁶Celgene Corporation, Warren, NJ, ⁷University Hospital Southampton, Southampton, United Kingdom
Background/Purpose: PsA, a chronic systemic inflammatory disease, reduces physical function and QOL. Treatment improves/maintains functionality. PALACE 1-3 compared apremilast (APR) efficacy/safety with placebo (PBO) in…
Abstract Number: 702 • 2015 ACR/ARHP Annual Meeting
Is Skin Disease More Important to Patients or Physicians in the Assessment of Disease Activity in Psoriatic Arthritis?
Dalton Sholter¹, Proton Rahman², J Antonio Avina-Zubieta³, John Kelsall⁴, Regan Arendse⁵, Majed M. Khraishi⁶, S Shaikh⁷, William G. Bensen⁸, Emmanouil Rampakakis⁹, John S. Sampalis¹⁰, Francois Nantel¹¹, May Shawi¹², Susan Otawa¹³, Cathy Tkaczyk¹³ and Allen J Lehman¹², ¹Rheumatology Associates, Edmonton, AB, Canada, ²Rheumatology, St. Clare's Mercy Hospital, St. John's, NF, Canada, ³Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁵University of Saskatchewan, Saskatoon, SK, Canada, ⁶Nexus Clinical Research, St Johns, NF, Canada, ⁷Niagara Peninsula Arthritis Centre, Hamilton, ON, Canada, ⁸St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁹JSS Medical Research, St-Laurent, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹²Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Patient (PtGA) and physician (MDGA) global assessment of disease activity are standard outcome measures used in clinical practice and research to ascertain patient and…
Abstract Number: 3117 • 2015 ACR/ARHP Annual Meeting
Under-Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease – an International Multicentre Study
Lihi Eder¹, Vinod Chandran¹, Cheryl Rosen², Jan Dutz³, James T. Elder⁴, Proton Rahman⁵, Christopher T. Ritchlin⁶, Francisco A. Tausk⁷, Sherry Rohekar⁸, Richard Hayday⁹, Snezana Barac¹⁰, Devy Zisman¹¹, Joy Feld¹² and Dafna D. Gladman¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴University of Michigan Medical School, Ann Arbor, MI, ⁵Computer Sciences, Memorial University of Newfoundland, St. John's, NF, Canada, ⁶Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁷University of Rochester Medical Center, Rochester, NY, ⁸Western University, London, ON, Canada, ⁹University of Manitoba, Winnipeg, MB, Canada, ¹⁰Winnipeg Clinic, Winnipeg, MB, Canada, ¹¹Rheumatology Unit, Carmel Medical Center, Haifa, Israel, ¹²Carmel Medical Center, Haifa, Israel
Background/Purpose: Cardiovascular risk in patients with psoriatic disease is partly attributed to the high prevalence of traditional cardiovascular risk factors in these patients. This study…
Abstract Number: 1057 • 2015 ACR/ARHP Annual Meeting
Are Ankylosing Spondylitis, Psoriatic Arthritis and Undifferentiated Spondylarthritis Associated with an Increased Risk of Cardiovascular Disease?
Karin Bengtsson¹, Helena Forsblad-d'Elia², Elisabeth Lie¹, Eva Klingberg¹, Mats Dehlin¹, Sofia Exarchou³, Ulf Lindström¹, Johan Askling⁴ and Lennart TH Jacobsson¹, ¹Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²Departments of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ³Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden
Background/Purpose: It is unclear whether and to what extent different phenotypes of spondylarthritis (SpA) are associated with an increased risk of cardiovascular events such as…
Abstract Number: 3207 • 2015 ACR/ARHP Annual Meeting
Axial Disease in Psoriatic Arthritis: A Clinical and Radiographic Comparison with Ankylosing Spondylitis
Deepak R. Jadon¹, Raj Sengupta¹, Alison L Nightingale², Mark Lindsay³, Eleanor Korendowych¹, Graham Robinson⁴, Amelia Jobling⁵, Gavin Shaddick⁶, Anne Barton⁷ and Neil J. McHugh⁸, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ³Pharmacy & Pharmacology, University of Bath, Bath, United Kingdom, ⁴Royal United Hospital, Bath, United Kingdom, ⁵Mathematical Sciences, University of Bath, Bath, United Kingdom, ⁶Department of Mathematics, University of Bath, Bath, United Kingdom, ⁷Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University Of Manchester, Manchester, United Kingdom, ⁸Rheumatology, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, United Kingdom
Background/Purpose: Little is known of the characteristics of psoriatic spondyloarthritis (PsSpA). A study was conducted to determine the: (i) prevalence of PsSpA in a psoriatic…
Abstract Number: 1565 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Improvement of Pain, Fatigue, and Disability in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials
Dafna D. Gladman¹, Vibeke Strand², Arthur Kavanaugh³, Philip J. Mease⁴, Christopher J. Edwards⁵, Maurizio Cutolo⁶, Frédéric Lioté⁷, Paul Bird⁸, Randall M. Stevens⁹, Lichen Teng⁹, Marla Hochfeld⁹ and Georg A. Schett¹⁰, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Stanford University, Portola Valley, CA, ³University of California San Diego, La Jolla, CA, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵University Hospital Southampton, Southampton, United Kingdom, ⁶Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁷Rheumatology Department, University Paris Diderot, Paris, France, ⁸Combined Rheumatology Practice, Kogarah, Australia, ⁹Celgene Corporation, Warren, NJ, ¹⁰Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].